StockData
Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc. (RLMD) stock

RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$2.85−0.15 (-5.15%)

Close on Nov 18, 2026Market cap $304.54MP/E –Yield –

Relmada Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Relmada Therapeutics's price to book ratio was 2.3× on Nov 11, 2026, against 15.8× a year earlier. Over the last 5 years it ranged from 0.0× to 16.9×, with a median of 1.6×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.3×−14.6
2025Dec 31, 202516.9×+16.6
2024Dec 31, 20240.3×−0.9
2023Dec 29, 20231.2×+1.2
2022Dec 30, 20220.0×−5.4
2021Dec 31, 20215.4×−35.6
2020Dec 31, 202041.0×−8.9
2019Dec 31, 201949.9×+24.5
2018Apr 30, 201825.4×+19.0
2017Dec 29, 20176.4×+4.1
2016Dec 30, 20162.4×+0.4
2015Dec 31, 20152.0×–

More Relmada Therapeutics figures

See a number that looks wrong?